VWF Antibody - #AF3000

>>奖励金 进行中>>
(17)   (8)  
产品: VWF 抗体
货号: AF3000
描述: Rabbit polyclonal antibody to VWF
应用: WB IHC IF/ICC
文献验证: WB, IHC, IF/ICC
反应: Human, Mouse, Rat
预测: Pig
蛋白号: P04275
RRID: AB_2837580

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1500 现货
 100ul RMB¥ 2500 现货

货期: 当天发货

联系销售
相关下载
MSDS
说明书
COA
实验方案
WB Handbook
IHC Protocol
IF/ICC Protocol

产品描述

来源:
Rabbit
应用:
IHC 1:50-1200, WB 1:500-1:2000, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Mouse, Rat
克隆:
Polyclonal
特异性:
VWF Antibody detects endogenous levels of total VWF.
RRID:
AB_2837580
引用格式: Affinity Biosciences Cat# AF3000, RRID:AB_2837580.
偶联:
Unconjugated.
纯化:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

Coagulation factor VIII; Coagulation factor VIII VWF; F8VWF; Factor VIII related antigen; von Willebrand antigen 2; von Willebrand antigen II; Von Willebrand disease; VWD; vWF; VWF_HUMAN;

抗原和靶标

免疫原:

A synthesized peptide derived from human VWF, corresponding to a region within the internal amino acids.

基因/基因ID:
VWF(7450)
描述:
Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V.

研究领域

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > ECM-receptor interaction.   (View pathway)

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Organismal Systems > Immune system > Complement and coagulation cascades.   (View pathway)

· Organismal Systems > Immune system > Platelet activation.   (View pathway)

文献引用

1). Endothelial CLEC5A drives barrier dysfunction and vascular leakage responsible for lung injury in bacterial pneumonia and sepsis. Science advances, 2025 (PubMed: 40498836) [IF=11.7]
2). Multi-omics analysis reveals the pre-protective mechanism of Dendrobium flexicaule polysaccharide against alcohol-induced gastric mucosal injury. International journal of biological macromolecules, 2025 (PubMed: 39730050) [IF=7.7]
3). CCDC134 enhances ovarian reserve function and angiogenesis by directly interacting with INHA in a mouse model of premature ovarian insufficiency. Apoptosis : an international journal on programmed cell death, 2025 (PubMed: 40042746) [IF=6.1]
4). OPN3-mediated positive regulation of angiogenesis in HUVECs through VEGFR2 interaction. Communications biology, 2025 (PubMed: 40164822) [IF=5.9]
5). Therapeutic efficacy of a co-blockade of IL-13 and IL-25 on airway inflammation and remodeling in a mouse model of asthma. International Immunopharmacology, 2017 (PubMed: 28282577) [IF=4.8]

Application: IHC    Species: mouse    Sample:

Fig. 5. Blockade of IL-13 and/or IL-25 decreases angiogenesis in the lung. (A) Representative photographs of von Willebrand factor (vWF)-positive (brown stained) peribronchial vessels. Original magnification ×20. Scale bar = 50 μm. (B) vWF-positive vessels per square millimeter. (C) Vascular endothelial growth factor (VEGF) levels in BALF. (D) Levels of VEGF in lung homogenates. The data are presented as the mean ± SEM (n = 6–7 per group). *P b 0.05 compared to the PBS/PBS group, #P b 0.05 compared to the OVA/IgG group, and &P b 0.05 compared to the single blocking group (OVA/sIL-13R or OVA/sIL-25R). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
6). Geniposide alleviates imiquimod-induced psoriasis-like skin lesions in mice via inhibition of angiogenesis. International immunopharmacology, 2024 (PubMed: 38565041) [IF=4.8]
7). NLRP3 inhibitor combined with Yimusake improves erectile dysfunction in rats with diabetes mellitus through the attenuation of pyroptosis. Heliyon, 2024 (PubMed: 39391494) [IF=4.0]
8). Wenyang Huazhuo Tongluo formula alleviates pulmonary vascular injury and downregulates HIF-1α in bleomycin-induced systemic sclerosis mouse model. BMC Complementary Medicine and Therapies, 2022 (PubMed: 35733188) [IF=3.9]

Application: IF/ICC    Species: Mouse    Sample:

Fig. 5Wenyang Huazhuo Tongluo Formula and KC7F2 can significantly inhibit the expression of vWF, SELE, ICAM-1 and VCAM-1 in bleomycin-induced SSc mouse model. The effect of Wenyang Huazhuo Tongluo Formula and KC7F2 on the expression of vWF (A), SELE (B), ICAM-1 (C) and VCAM-1 (D) was observed by immunofluorescence staining. compared with the PBS group, bleomycin can significantly upregulate the expression levels of vWF, SELE, ICAM-1 and VCAM-1 in endothelial cells, while Wenyang Huazhuo Tongluo Formula and KC7F2 can significantly reverse the bleomycin-induced upregulation of vWF, SELE, ICAM-1 and VCAM-1. The mean values ± SD was shown for each bar. * (P < 0.05) or ** (P < 0.01) or *** (P < 0.001) represents significance, ns represents no significance. Original magnification: × 20. BLM: Bleomycin, WYHZTL: Wenyang Huazhuo Tongluo formula
9). Exploration and validation of the hub genes involved in hypoxia-induced endothelial-mesenchymal transition of systemic sclerosis. Clinical and experimental rheumatology, 2023 (PubMed: 37246768) [IF=3.4]
10). Tanshinone I alleviates steroid-induced osteonecrosis of femoral heads and promotes angiogenesis: in vivo and in vitro studies. Journal of orthopaedic surgery and research, 2023 (PubMed: 37391758) [IF=2.8]

Application: IHC    Species: Rat    Sample:

Fig. 2 Effects of TsI on angiogenesis in femoral heads of rats with SIONFH. a Immunohistochemical staining for CD31 and VWF in femoral heads of rats (magnification 400 ×; scale bars: 50 μm). b Western blot analysis for expression levels of VEGF and VEGFR2 in femoral heads of rats. **P 

Application: WB    Species: human    Sample: EA.hy926 cells

Fig. 5 Effects of TsI on the angiogenic property of EA.hy926 cells exposed to DEX. EA.hy926 cells were treated with 20 μM TsI and/or 10 μM DEX for 48 h. a The wound-healing assay showed the migration capability of EA.hy926 cells. b The tube formation assay was used to measure the angiogenesis activity of EA.hy926 cells. c The expression levels of VEGF, CD31, and VWF were measured by Western blot analysis. Magnification 100 ×; scale bars: 200 μm. **P 
加载更多

限制条款

产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）

产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.